Solutions

Online Inquiry

Global Services. (Creative Biolabs Authorized)

AI-Integrated Tumor Antigen Discovery Service for CAR-T Development

Online Inquiry

Background Service What We Can Offer Workflow Highlights FAQs Related Services Contact

Creative Biolabs provides an AI-Integrated Tumor Antigen Discovery Service to address challenges in immunotherapy development, including prolonged drug-discovery timelines and the difficulty of identifying truly immunogenic surface targets within large-scale, multi-omics datasets. This service enables the rapid discovery of novel, high-confidence neoantigens to support the development of highly specific antibodies and personalized cancer vaccines. By combining advanced deep learning architectures with high-throughput screening platforms, Creative Biolabs converts complex genomic and immunological data into actionable therapeutic targets, accelerating the progression from antigen discovery to precision immunotherapy development.

Introduction

Tumor neoantigens, arising from non-synonymous mutations, represent the holy grail of personalized immunotherapy due to their high tumor specificity and lack of central tolerance. Traditional identification methods are often too slow and resource-heavy for clinical use. By leveraging deep learning, we can now model complex pMHC-TCR interactions in silico, reducing candidate generation time by 60%.

Service

Creative Biolabs provides a solution for researchers seeking to identify the needle in the haystack, those rare, tumor-specific epitopes that trigger a robust immune response. We deliver a prioritized list of candidate antigens validated for MHC presentation and TCR recognition, ensuring your project moves from data to the clinic with maximum confidence.

Our platform offers target identification via AI-assisted mining of genomic, transcriptomic, and proteomic datasets to discover tumor‑specific surface antigens with high tumor selectivity and minimal normal‑tissue expression, provides deep learning‑driven evaluation by computationally predicting antigen accessibility, structural exposure, and epitope suitability while ranking targets through multi‑parameter scoring models, and delivers translational immunotherapy support with target selection optimized for downstream CAR, antibody, or TCR engineering and integrated reports for preclinical development and therapeutic design.

Discover How We Can Help - Request a Consultation.

What We Can Offer

Creative Biolabs integrates multiple analytical platforms to support tumor antigen discovery with high accuracy and scalability.

Multi-Omics Data Integration

Integrated analysis of genomic mutations, transcriptomic expression profiles, and proteomic datasets to identify tumor-specific molecular signatures and prioritize membrane-associated proteins.

Deep Learning Target Prediction

Neural network models analyze complex biological datasets to predict antigen specificity, tumor selectivity, and therapeutic feasibility.

Surface Proteome Profiling

Computational prediction of cell-surface localization combined with membrane protein annotation to identify accessible therapeutic targets.

Structural Accessibility Analysis

3D structural modeling and epitope exposure evaluation help identify regions suitable for antibody or receptor binding.

Immunogenicity and Target Prioritization

Integrated scoring systems evaluate antigen expression specificity, tumor coverage, and predicted immunogenic potential to guide target selection.

Our Workflow

Required starting materials include tumor genomic sequencing data, such as whole exome or whole-genome datasets, transcriptomic datasets, and public or proprietary proteomic datasets associated with tumor cell surface proteins.

Workflow of AI-Integrated Tumor Antigen Discovery. (Creative Biolabs Original)

Final Deliverables:

A comprehensive Antigen Prioritization Report featuring ranked neoantigen candidates with detailed immunogenicity scores.

Raw and processed Bioinformatic Datasets and structural modeling files for top-tier candidates.

Core Benefits

Customized Deep Learning Pipelines: Tailored neural network architectures optimized for specific cancer types or rare HLA alleles.
Deep Mutational Scanning (DMS) Support: Utilizing high-throughput mutational data to optimize antigen affinity and stability.
Explainable AI Frameworks: Transparent modeling processes that provide a scientific rationale behind each predicted lead to satisfy regulatory expectations.
Scalable Cloud Computing Platform: Rapid processing of massive datasets via GPU-accelerated environments for global accessibility.

FAQs

Q: How does AI improve the true positive rate of neoantigen discovery?

A: Traditional tools only look at binding affinity. Creative Biolabs AI integrates extra layers like proteasomal cleavage efficiency, TCR recognition propensity, and peptide hydrophobicity, which filter out 98% of binders that fail to elicit a real immune response.

Q: Can your service handle rare HLA alleles?

A: Yes. While many tools are biased toward common alleles, our pan-specific models and transfer learning techniques allow us to predict targets for underrepresented and rare HLA haplotypes.

Q: Do you offer support for non-coding region antigens?

A: Our pipelines are increasingly focused on epitopes derived from non-coding regions and alternative splicing, which represent a vast and underexplored reservoir of immunogenic targets.

Q: Is the data kept confidential?

A: Creative Biolabs adheres to strict data privacy standards and regulatory compliance, ensuring all client-provided genomic data is handled with the highest levels of security and ethical transparency.

Related Services

AI-Enhanced TCR-pMHC Affinity Modeling Service

Creative Biolabs utilizes AI-based structural modeling and energy prediction to analyze TCR–pMHC interactions. Our platform enables rapid evaluation of binding affinity and stability, supporting efficient selection of high-performance TCR candidates.

Learn More →

AI-Guided Epitope Mapping & Analysis Service

Creative Biolabs integrates neural network prediction with structural analysis to map antigen epitopes and binding interfaces. This service supports optimized CAR and TCR design by improving target specificity and functional performance.

Learn More →

AI-Optimized Binder Humanization Service

We leverage advanced machine learning to rationally humanize binders, enhance affinity and stability, minimize immunogenicity, and accelerate the development of safe and effective therapeutic candidates.

Learn More →

Partner with Us

Creative Biolabs is dedicated to accelerating the future of personalized oncology through the power of AI-Integrated Tumor Antigen Discovery. Whether you are identifying shared driver mutations or developing a bespoke patient vaccine, our platform provides the precision and speed necessary to succeed in today's competitive biopharmaceutical landscape. Please feel free to contact our team for more detailed information, expert technical support, and in-depth discussions about your unique project requirements and development goals.

All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.